# US 10,481,165 B2 · Elevated CCL19 after completion of therapy for acute lyme disease identifies patients at risk for development of post-treatment lyme disease syndrome who will benefit from further antibiotic therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,481,165 B2
- Document ID: US10481165B2
- Status: Granted
- Kind: B2
- Application number: 16/058,316
- Filed: 2018-08-08
- Published: 2019-06-13
- Granted: 2019-11-19
- Earliest claimed: 2015-04-16
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: John N. Aucott; Mark J. Soloski
- Web page: https://patentgrep.com/patent/US10481165B2

## CPC

- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/65: Tetracyclines
- G01N 2333/43556: from ticks
- G01N 2333/521: Chemokines
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to the field of Lyme disease. More specifically, the present invention provides methods and composition useful for the treatment of Lyme disease. In one aspect, the present invention provides compositions and methods for treating a patient at risk for or likely to develop post-treatment Lyme disease syndrome (PTLDS). In certain embodiments, the patient is already undergoing a first course of antibiotic treatment for Lyme disease. In a specific embodiment, a method comprises the step of prescribing or administering a second course of antibiotic treatment to a patient who is determined to have an increased level of CCL19 as compared to a control after completing a first course of antibiotics for Lyme disease.

## Claims

### Claim 1

A method for treating a patient likely to develop post-treatment Lyme disease syndrome (PTLDS) and who is currently undergoing a first course of antibiotic treatment for Lyme disease comprising the step of prescribing or administering a second course of antibiotic treatment to a patient who is determined to have an increased level of CCL19 as compared to a control after completing a first course of antibiotics for Lyme disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the second course of antibiotics comprises an antibiotic that is different from the first course of antibiotics.